Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.

@article{Vestbo2016FluticasoneFA,
  title={Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.},
  author={J\orgen Vestbo and Julie Anne Anderson and Robert D. Brook and Peter M. A. Calverley and Bartolome R Celli and Courtney C Crim and Fernando J Martinez and Julie Carol Yates and David E. Newby},
  journal={Lancet},
  year={2016},
  volume={387 10030},
  pages={1817-26}
}
BACKGROUND Chronic obstructive pulmonary disease (COPD) often coexists with cardiovascular disease. Treatments for airflow limitation might improve survival and both respiratory and cardiovascular outcomes. The aim of this study was to assess whether inhaled treatment with a combined treatment of the corticosteroid, fluticasone furoate, and the long-acting β agonist, vilanterol could improve survival compared with placebo in patients with moderate COPD and heightened cardiovascular risk… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 35 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 57 extracted citations

Ectopic adiposity and cardiometabolic health in COPD

International journal of chronic obstructive pulmonary disease • 2018
View 16 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Cardiovascular events in patients with chronic obstructive pulmonary disease : TORCH study results

Calverley PMA, JA Anderson, B Celli
Thorax • 2010

on behalf of the TORCH investigators. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results

PMA Calverley, JA Anderson, B Celli
Thorax • 2010

Similar Papers

Loading similar papers…